Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide in mild to moderate COVID-19
NCT04870606Phase 3Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of proxalutamide in coronavirus disease 2019 (COVID-19), sponsored by Kintor Pharmaceutical Limited. Started Mar 2021; status: completed.
02
Drugs
proxalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04870606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870606.